OP0073 COLCHICINE TWICE DAILY FOR HAND OSTEOARTHRITIS: RESULTS FROM THE DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED COLOR TRIAL
Authors: A. Døssing, M. Henriksen, K. Ellegaard, S. M. Nielsen, L. Stamp, F. C. Müller, M. Kloppenburg, I. Haugen, G. Mccarthy, P. G. Conaghan, L. Dahl, L. Terslev, R. Altman, F. Becce, E. Ginnerup-Nielsen, L. Jensen, M. Boesen, R. Christensen, U. Dal, H. Bliddal
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Colchicine has been suggested as a treatment for osteoarthritis symptoms, but evidence is contradictory.<sup>[1]</sup> <h3>Objectives</h3> To investigate the clinical efficacy and safety of colchicine compared with placebo in people with hand osteoarthritis. <h3>Methods</h3> In this double-blind, randomised, placebo-controlled trial we recruited adults from a dedicated outpatient clinic in Denmark. Eligibility criteria included symptomatic hand osteoarthritis and finger pain of at least 40 mm on a 100-mm visual analogue scale (VAS). The hand with the most severe finger pain at inclusion was considered the target hand. Participants were randomly assigned to 0.5 mg colchicine or placebo taken orally twice daily for 12 weeks. The primary endpoint was change from baseline to week 12 in target hand finger pain, assessed on a 100-mm VAS with a pre-specified minimal clinically important difference of 15 mm, in the intention-to-treat population. The study was registered prospectively at ClinicalTrials.gov, NCT04601883. <h3>Results</h3> We screened 186 people for eligibility between January 15, 2021 and March 3, 2022 and randomly assigned 100 participants: 50 (50%) to colchicine and 50 (50%) to placebo. All participants completed the study. The mean changes from baseline to week 12 in finger pain were -13.9 mm (SE 2.8) in the colchicine group, and -13.5 mm (2.8) in the placebo group with a between-group difference (colchicine versus placebo) of -0.4 mm (95% CI -7.6 to 6.7; p = 0.90). The efficacy on primary and secondary outcomes is summarized in the Table 1. In the colchicine group, there were 76 adverse events in 36 (72%) participants and one serious adverse advent. In the placebo group, there were 42 adverse events in 22 (44%) participants and two serious adverse events. Serious adverse events were unrelated to treatment. <h3>Conclusion</h3> In people with painful hand osteoarthritis, treatment with 0·5 mg of colchicine twice daily for 12 weeks did not effectively relieve pain and treatment with colchicine was associated with more adverse events. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Anna Døssing: None declared, Marius Henriksen Employee of: MH in on the European Advisory Board for Thuasne Group, Karen Ellegaard: None declared, Sabrina Mai Nielsen: None declared, Lisa Stamp Consultant of: LKS has received consulting fees from Pharmac, Felix C Müller Speakers bureau: FCM has received payment or honoraria from Varian and Siemens Healthineers., Margreet Kloppenburg Speakers bureau: MGK has received payment or honoraria from Galapagos and Jansen, Consultant of: MGK has received consulting fees for Abbvie, Pfizer, Kiniksa, Flexion, Galapagos, CHDR, Novartis, and UCB, Grant/research support from: MGK has received royalties or licenses from Wolters Kluwer and Springer Verlag, Ida Haugen Speakers bureau: IKH has received payment or honoraria from Novartis and GSK, Grant/research support from: IKH has received grants from Pfizer/Lily (ADVANCE), Geraldine McCarthy Grant/research support from: GMcC has received support for attending meeting from Janssen, Philip G Conaghan Speakers bureau: PGC has received payment or honoraria from AbbVie, Consultant of: PGC has received consulting fees from AbbVie, AstraZeneca, Eli Lilly, Galapagos, GlaxoSmithKline, Grunenthal, Janssen, Levicept, Merck, Novartis, Pfizer, Regeneron, Stryker, and UCB, Grant/research support from: PGC has received support from AbbVie for congress attendance., Louise Dahl: None declared, Lene Terslev Speakers bureau: LT has received payment or honoraria from Eli Lilly, Novartis, and Janssen, Employee of: LT is on the advisory board for BMS and Janssen., Roy Altman: None declared, Fabio Becce Consultant of: FB has received consulting fees from Horizon Therapeutics., Elisabeth Ginnerup-Nielsen: None declared, Lene Jensen: None declared, Mikael Boesen: None declared, Robin Christensen: None declared, Ulla Dal: None declared, Henning Bliddal: None declared.